Cerevel Therapeutics Holdings Inc (CERE)
42.55
-0.04
(-0.09%)
USD |
NASDAQ |
May 03, 16:00
42.55
0.00 (0.00%)
After-Hours: 20:00
Cerevel Therapeutics Holdings Cash from Operations (TTM): -342.30M for Dec. 31, 2023
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
Date | Value |
---|---|
December 31, 2023 | -342.30M |
September 30, 2023 | -332.36M |
June 30, 2023 | -340.13M |
March 31, 2023 | -320.46M |
December 31, 2022 | -293.19M |
September 30, 2022 | -258.45M |
June 30, 2022 | -221.82M |
Date | Value |
---|---|
March 31, 2022 | -209.78M |
December 31, 2021 | -178.55M |
September 30, 2021 | -167.50M |
June 30, 2021 | -143.81M |
March 31, 2021 | -124.77M |
December 31, 2020 | -117.80M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-342.30M
Minimum
Dec 2023
-117.80M
Maximum
Dec 2020
-234.69M
Average
-221.82M
Median
Jun 2022
Cash from Operations (TTM) Benchmarks
AbbVie Inc | 22.69B |
Immunogen Inc (DELISTED) | -197.89M |
Bristol-Myers Squibb Co | 13.72B |
Madrigal Pharmaceuticals Inc | -324.23M |
Adverum Biotechnologies Inc | -90.90M |